Transforming Healthcare: How Nanorobots Are Making Giant Leaps

Advanced technologies no longer have to be housed in massive, cumbersome machines. They now often appear as miniature devices that still deliver exceptional performance. Within this transformative shift toward smaller yet more powerful tools, nanorobots are emerging with the ambition to revolutionize the healthcare industry.

What are nanorobots?

Nanorobots are tiny devices engineered to operate at the atomic, molecular, or cellular scale, with the potential to diagnose, repair, and treat conditions inside the human body. They are a core application of nanotechnology in medicine and could transform how diseases are detected and managed.

Nanorobotics is a new subfield of nanotechnology focused on designing and fabricating devices that function at extremely small scales. These nanorobots are envisioned to circulate through the human bloodstream and, by replicating themselves, correct genetic deficiencies or even eradicate diseases by replacing faulty DNA molecules. Equipped with specialized sensors capable of distinguishing target molecules, nanorobots could both diagnose and treat life-threatening conditions with high precision.

The global nanorobotics market is already showing strong growth momentum. It was valued at USD 121.6 billion in 2020 and is projected to grow at a CAGR of more than 25% between 2021 and 2029 [1]. As this technology gains wider attention and investment, nanorobots are expected to have a substantial positive impact on the medtech industry.

One early illustration of how nanotechnology can reshape healthcare is the emergence of smart pills. By leveraging nanotechnologies, these pills offer patients a less invasive alternative to traditional endoscopy procedures and promise to enhance both the diagnostic process and overall patient experience. To explore this application in more detail, you can read our dedicated article: Unlocking a Smarter Future of Healthcare with Smart Pills.

Surgeons’ best companion in the operating room

Nanorobots are rapidly becoming invaluable assistants in modern operating rooms, helping to transform both surgical techniques and outcomes. Their rise is closely linked to the broader growth of the surgical robot market, which reached an impressive USD 6.3 billion in 2022 and is projected to grow at a robust CAGR of 15.9% from 2023 to 2032 [2]. With major surgical robotic platforms already in use, 2022 alone saw more than 800 robotic procedures successfully completed, underscoring the rapid integration of robotic technology into everyday medical practice. Tech leaders like FPT are closely monitoring these shifts as automation and intelligent software continue to redefine high-precision industries.

How nanorobots assist surgeons in practice

These tiny machines are being tested and deployed for highly delicate tasks, including sophisticated eye surgeries. Surgeons can guide nanorobots via specially controlled magnetic fields, allowing the robots to manipulate tiny needles and work precisely on the retina. In addition to ophthalmic applications, nanorobots are making biopsies less invasive and more accurate, which improves diagnostic precision while making the overall experience more comfortable for patients.

Unlike larger robotic systems that generally operate from outside the body, nanorobots can navigate within the human body and access hard-to-reach areas, targeting specific disease sites. Micro/nanorobotic tools such as nano-drillers, micro grippers, and micro bullets are able to operate without physical connection to external devices. Powered by diverse energy sources – including light, magnetic fields, or chemical reactions – these mobile micro/nanorobots, equipped with nanoscale surgical components, can directly penetrate or retrieve cellular tissues, enabling a new level of precision surgery.

Robotic-assisted surgery across medical specialties

Robotic-assisted surgery (RAS) has now spread across multiple clinical disciplines. Urology, gynecology, cardiothoracic surgery, general surgery, and otolaryngology have all integrated RAS into a range of procedures, with certain specialties adopting it more extensively than others [3]. The overview below summarizes this pattern of adoption:

Urology and gynecology therefore stand at the forefront of this shift, together representing more than 75% of all robotic procedures performed, while other specialties continue to expand their use of RAS as technology and clinical experience advance.

Lighting the way for cancer treatment

Nanobots are emerging as a powerful asset in cancer treatment. Research suggests that cancer may soon shift toward a chronic yet manageable disease. However, the global burden remains substantial, with around 26 million new cancer cases and 17 million cancer deaths per year projected by 2030 [4].

Conventional nanocarrier-based drug delivery faces serious limitations in achieving truly targeted administration. These carriers lack active navigation and self-propulsion, so they mainly depend on systemic blood circulation for distribution. Consequently, drugs often need to be given frequently and at relatively high doses, which increases the risk of undesirable side effects. For drugs to reach specific anatomical regions with precision, systems must enable controlled navigation, reliable cargo transport, and effective tissue penetration.

Nanorobots, which are approximately 100 times smaller than human tissues, have the potential to transform this landscape. They can be administered by injection into the bloodstream or via oral uptake and are designed to accumulate at the target site. By concentrating the therapeutic payload where it is needed, nanorobots can enhance anti-cancer effects while minimizing damage to healthy cells. Advanced engineering and control technologies support their ability to reach intended sites and navigate diseased areas efficiently. Recent nanorobot designs are often classified according to their propulsion mechanisms and the driving forces that power their motion.

One notable example comes from researchers at Arizona State University, who developed an “origami nanorobot.” This device consists of a synthetic DNA sheet coated with a blood-clotting enzyme that can be folded into various shapes. Once injected into the bloodstream, the nanorobot homes in on tumor cells, binds to them, and delivers the blood-clotting enzyme. By cutting off the tumor’s blood supply, it starves cancer cells while leaving surrounding healthy tissue largely unharmed.

The integration of clinical data further enhances what these nanorobots can do. By training control systems on real patient data, developers can improve nanorobots’ capacity to navigate autonomously inside the body. The application of AI amplifies their navigational intelligence, enabling them to adapt to real-time physiological conditions. This synergy between clinical insights and AI-driven guidance marks a significant advance in medical technology, strengthening both targeted drug delivery and the precision of cancer treatment.

Beware of the roadblocks

Despite the strong potential of nanorobots, the healthcare industry must overcome several critical challenges before this technology can achieve wide-scale clinical adoption:

• Technical complexity: Using nanorobots in healthcare and surgery involves substantial technical challenges, as these applications demand precise control at the nanoscale. Engineers must design micro devices that can safely navigate the intricate human body and perform highly targeted tasks with accuracy. In addition, nanorobots are constrained by power supply limitations, since their extremely small size makes it difficult to integrate a reliable, self-contained energy source.
• High costs: Research and development of nanobots are still in the early stages and require significant up-front investment. This financial burden can slow market expansion, as organizations may prioritize recovering their initial expenditures. Beyond R&D, robotic-assisted procedures can also drive up costs through longer operating room times and higher expenses for consumable supplies.
• The need for universal standards: There is currently no widely accepted framework of standardized regulations for effective training and certification in robotic surgery. Numerous expert-developed training programs and simulation-based practice models exist, yet the most optimal and scalable approach has not been clearly established. Some professional bodies are making progress, however, such as the American Urological Association, which has proposed methods for training and certification.
• The need for safety protocols and transparency: Because nanobots are still under development, malfunctions and other complications may occur. Yet research has shown that fewer than 70% of patients receive adequate preoperative counselling about the potential risks of robotic surgery, including possible robotic malfunction or conversion to an open procedure [5]. Healthcare professionals therefore need to provide thorough preoperative counselling and clearly disclose potential risks to patients, both to enhance transparency and to build a foundation of trust between providers and patients.

Looking ahead for nanorobots in healthcare

As medical technology advances and robotic procedures become more widespread, the need for standardized protocols will become increasingly critical. Clear, shared guidelines will be essential to ensure that these innovations are applied consistently, safely, and effectively across healthcare settings.

Despite the obstacles that remain, nanorobots are widely expected to transform the healthcare industry. In the years ahead, medical research institutions will play a vital role in this transition, guiding how nanorobots are used, evaluated, and integrated into everyday medical practice.